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Abstract— Troponin, a contractile protein of the thin filament 
of striated muscle, consists of three subunits: troponin C (TnC), 
troponin T (TnT), and troponin I (TnI). Cardiac troponin I 
(cTnI) plays a critical role in regulation of cardiac function. The 
physiological effect of cTnI, as an inhibitory subunit of troponin 
complex, is to prevent the interaction between myosin heavy 
chain heads and actins, i.e. the cross-bridge formation, and to 
ensure a proper relaxation of cardiac myofilaments. In 
pathological conditions, the deficiency of cTnI or mutations in 
cTnI especially in the C-terminus of cTnI is associated with 
diastolic dysfunction caused by myofibril hypersensitivity to 
Ca2+. Our laboratory has generated cTnI knockout mouse model 
to investigate the cellular and molecular function of cTnI and 
created cTnI mutant disease mouse models to explore the 
pathophysiology caused by cTnI mutations in the heart. Here, we 
present our recent studies on physiological function of cTnI in 
the heart and the pathological consequences caused by the cTnI 
mutations in the diseased heart using the transgenic mouse 
models. The mechanisms underlying diastolic dysfunction and 
heart failure caused by cTnI mutations are explored in cell-based 
assays and in transgenic animal models. These studies provide us 
with useful information in searching for therapeutic strategies 
and target-oriented medication for the treatment of diastolic 
dysfunction and heart failure. 
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I.  INTRODUCTION  
Heart failure is a leading cause of mortality in the United 
States. Up to 40% of heart failure patients have impaired 
relaxation, known as diastolic dysfunction and diastolic heart 
failure with normal systolic performance. Diastolic heart 
failure is an important clinical syndrome and both hypertrophic 
cardiomyopathy (HCM) and restrictive cardiomyopathy 
(RCM) share the same feature of diastolic dysfunction. It is 
known that single cardiac myofibril gene mutations are 
associated with cardiomyopathies leading to diastolic heart 
failures. However, the mechanisms underlying the impaired 
relaxation in myocardial cells and diastolic dysfunction 
developed in the heart are unknown. There is a critical need to 
understand the mechanisms that cause diastolic dysfunction 
and heart failure and to develop target-based intervention and 
medications to correct the overt condition and to treat the 
patients. For the moment, in the absence of such agents and 
intervention, treatment of diastolic dysfunction is difficult and 
often ineffective [1]. Our laboratory is among the first in 
studying the molecular mechanisms and pathophysiology of 
diastolic dysfunction and diastolic heart failure in transgenic 
mouse models. We have generated cardiac troponin I (cTnI) 
gene knockout mouse model [2] and transgenic mice with cTnI 
C-terminal mutations [3, 4]. Using these animal models, we 
have explored the physiological roles of troponin in cardiac 
muscle movement and cardiac function and revealed the 
mechanisms underlying cardiac dysfunction and heart disorders 
caused by the troponin mutations in myocardial cells.  
II. MATERIALS AND METHODS 
A. Generate cTnI knockout mouse model 
Homologous recombination in embryonic stem (ES) cells 
was used to delete the entire cTnI gene from the mouse 
genome. In cTnI gene knockout mice (cTnI-KO), all 
homozygous mutants die on days 17 or 18 after birth, whereas 
the heterozygous mutants have a similar life span as that of the 
wild type mice [2]. By crossing two heterozygous mutants, we 
receive homozygous, heterozygous and wild type offspring for 
our studies.  
B. Create transgenic mice with RCM cTnI mutations 
Our laboratory has created transgenic (TG) mice containing 
the RCM cTnI R193H and K178E mutations reported by 
Mogensen [5] and transgenic RCM mice containing the 
mutation R205H in the mouse genome corresponding to cTnI 
R204H mutation discovered in human RCM patients [6, 7]. 
The transgenic mice carrying RCM cTnI R193H mutation 
(cTnI193His) had 20-40% mortality rates and developed RCM 
phenotype similar to that observed in RCM patients [3]. 
However, cTnI178Glu and cTnI205His mice were lethal and died a 
couple of days after birth. By crossing the cTnI193His mice with 
heterozygous cTnI-KO mice, we generated various transgenic 
mouse lines expressing different levels of cTnI R193H in 
myocardial cells [8]. 
C. Monitor cardiac fucntion in vivo 
We have analyzed the dose-dependent negative effect of 
cTnI193His in RCM TG mice. The mortality rate was monitored 
and recorded in the different transgenic lines and their cardiac 
function was measured to determine any functional change 
related to the expression level of cTnI193His. Cardiac function 
assessments were performed by using a Vevo 770 High-
resolution In Vivo Imaging System from VisualSonics (Toronto, 
ON, Canada). 10 mice (5 males and 5 females) per line 
including wild type were analyzed. The animals were first 
anesthetized with isoflurane at a concentration of 5% and then 
maintained at 1.1% isoflurane by a facemask during the 
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procedure. Mouse body temperature and ECG measurement 
were taken during the whole process. The ventricular chamber 
sizes during systole and diastole, and the septal and ventricular 
wall thickness were measured through M mode imaging. B 
mode imaging 4-chamber view was taken to measure atrial size. 
The mitral inflow was evaluated with the Pulse-Wave Doppler 
and the following parameters measured: early ventricular 
filling (E wave); late ventricular filling caused by atrial 
contraction (A wave); ejection time (ET); isovolumetric 
relaxation time (IVRT); deceleration time (DT); isovolumetric 
contraction time (IVCT). Doppler Tissue Imaging (DTI) 
analyses were also performed to determine the mitral annulus 
velocity in the hearts. The E/A, E’/A’ and E/E’ ratios were 
calculated as reported previously [3, 8-10]. 
D. Cell-based assays 
 Myocardial cells were isolated freshly from experimental 
mouse hearts. The following cell-based assays were performed 
on these myocardial cells. 
1) Determination of the sarcomere length and myofibril 
conformation. The resting sarcomere length in both WT and 
RCM myocardial cells was measured using the IonOptix 
system (IonOptix Co., Milton, MA) as reported previously [9, 
10]. Cardiac myocytes were isolated with a Langendorff 
perfusion cell isolation system (Cellutron) using the 
manufacturer’s protocol and cultured in mouse myocyte 
culture medium provided by the same company. An Olympus 
IX 71 microscope was used to visualize the cells. The 
myocardial cells isolated from the different lines of RCM TG 
and WT mouse hearts were field stimulated at 37º C, at 8 volts 
and frequencies varying from 0.2, 0.5, 1.0, to 2.0 Hz. At each 
frequency, a minimum of 12 contractions were used for the 
myocyte to achieve a steady state and 10 subsequent 
contractions were recorded for analysis. Cardiac myocytes’ 
sarcomere length at end diastolic stage for the different 
transgenic lines was measured and compared to that of WT 
cells.  
2) Determine the calcium dynamics in myocardial cells. The 
calcium transients on the cardiomyocytes isolated from the 
various RCM transgenic lines and the WT mice were measured 
as reported previously [8, 10]. Freshly isolated cardiomyocytes 
were loaded with 2 µM of fura-2 AM (Molecular Probes) for 
20 minutes at room temperature in Tyrode’s solution 
containing (in mM): 131 NaCl, 4 KCl, 1 CaCl2, 1 MgCl2, 10 
Glucose, 10 HEPES, at pH 7.4 with 1% BSA and 0.02% 
pluronic F-127 (Molecular Probes). After 30 minutes of de-
esterification of the fura-2 AM, the cells were bathed in Tyrode 
solution. For measurement, the fura-2 loaded cardiomyocytes 
were excited by UV light (360 and 380 nm, alternately) and the 
fura-2 emission wavelength (510 nm) was recorded with a 
photomultiplier tube. The kinetics of Ca2+ transients were 
analyzed in conjunction with myocyte mechanical 
measurements. 
III. RESULTS 
A. Phenotype of cTnI deficiency in cTnI-KO mice 
Two main TnI genes are expressed in the mammalian heart 
under the control of a developmentally regulated program. 
Fetal TnI, which is identical to slow skeletal TnI (ssTnI), is 
expressed first and predominates throughout embryonic and 
fetal development. Around embryonic day 10, cTnI begins to 
be expressed. Soon after birth, cTnI accounts for roughly half 
of the total thin-filament TnI content, and then cTnI 
predominates throughout adulthood in most animals, including 
humans. In the cTnI-KO mice, ssTnI was found to compensate 
for the absence of cTnI, but only temporarily, as ssTnI was 
eventually down-regulated in the cTnI-KO mouse heart.  
Since ssTnI could be down-regulated as usual during the 
TnI isoform switch, a mammalian model with a myocardial TnI 
deficiency was created in homozygous mutants about two 
weeks after birth and all these homozygous mutant mice died 
on day 18 after birth when the TnI content was declined below 
40% of the total TnI amount in the heart [2]. The histological 
and functional measurement results clearly showed that TnI 
depletion altered both resting and active mechanical properties 
of ventricular myocytes and caused a lethal phenotype with 
shortened sarcomere length and a restricted ventricle due to a 
severe diastolic dysfunction [2, 11]. The results also showed 
for the first time that expression of the adult cTnI isoform is 
not an essential component of the switch that terminates 
expression of the fetal ssTnI expression in the developing 
heart. This mouse strain with its predictable time-dependent 
loss of TnI is useful in our later investigations to establish the 
effects of TnI depletion on cardiac function in vivo.  
B. Phenotype of cTnI mutations in RCM cTnI193His mice 
Our laboratory has been among the first to begin to define 
the effect of the RCM cTnI mutation on the development of 
diastolic dysfunction. We have created transgenic mice 
(cTnI193His) expressing human RCM mutation cTnI R192H 
(cTnI R193H in mouse sequence) in the heart. The cTnI193His 
mice do not present with significant hypertrophy or ventricular 
dilation. They have a phenotype similar to that in human RCM 
patients carrying the same mutation characterized 
morphologically by enlarged atria and restricted ventricles and 
functionally by diastolic dysfunction and diastolic heart failure 
[3]. We have demonstrated that impaired relaxation is a main 
manifestation in the RCM cTnI transgenic mice [9].   
C. Cellular and molecular mechanisms of RCM cTnI 
mutations 
The results from the cell-based assays demonstrated that 
impaired relaxation was a key that causes restricted ventricle in 
the RCM cTnI R193H mice [9]. Calcium pCa curve 
measurement data indicated a significant curve left-shift in 
myofibers from the RCM cTnI193His mice, indicating an 
increase of myofibril sensitivity to Ca2+ [10]. The data obtained 
from Ca2+ transient measurements and biochemical assays 
indicated that cTnI mutation caused myofibril Ca2+ 
hypersensitivity was a key factor resulting in a delayed calcium 
drop-off from the myofilaments and a delayed relaxation time 
[10, 12]. 
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D. Experimental animal assays 
Based on our studies, we have demonstrated that Ca2+ 
hypersensitivity in myocardial cells caused by RCM cTnI 
mutations is a key that results in a delayed Ca2+ drop-off rate 
and an impaired relaxation. To confirm this, we have carried 
out experimental animal assays to desensitize the 
hypersensitivity in the RCM myocardial cells.  
1) Correct of Ca2+ hypersensitivity by cTnI-ND in RCM 
cTnI193His mice  
Proteolysis of the N terminal of cTnI (cTnI-ND) occurs as a 
functional adaptation in simulated microgravity and also under 
physiological and stress conditions [13]. The phosphorylable 
serine residues 23 and 24 are eliminated because of the 
truncation and the interaction of cTnI with TnC altered. The 
myofilament Ca2+ sensitivity was decreased in the presence of 
cTnI-ND and diastolic function improved. The therapeutic 
effect of this cTnI desensitizing molecule was investigated in 
our RCM cTnI193His mice presenting damaged diastolic 
function. Double transgenic mice (Double-TG) were created 
that express both cTnI-ND and the cTnI R193H in the heart. 
The results indicated that Ca2+ sensitivity was restored in the 
animals accompanied with improved diastolic function and 
increased life span [10]. Such findings confirm that calcium 
desensitization is a promising alternative to restore diastolic 
function in RCM hearts and highlight the need to further 
explore this therapeutic option.  
2) Reverse diastolic dysfunction by chemical Ca2+ desensitizer 
catechins in RCM cTnI193His mice 
There is a great need to develop or find small molecules and 
chemical Ca2+ desensitizers that can be used to alter myofibril 
sensitivity for Ca2+ and myofilament sliding kinetics. A great 
concern about biological agents is their non-toxicity and their 
good bioavailability but there are few Ca2+ desensitizers 
possessing such qualities. The catechin, (-)-epigallocatechin-3-
gallate (EGCg) has been newly found to possess Ca2+ 
desensitizing abilities via its interaction with cTnC [14, 15]. 
This compound is the most abundant catechin in green tea and 
is credited for the numerous health benefits attributed to green 
tea consumption. EGCg desensitizes myofilament to Ca2+ by 
forming a ternary complex with the C-terminal domain of 
troponin C and the anchoring region of cTnI [15]. The affinity 
of TnC to Ca2+ is reduced as a result which facilitates cardiac 
relaxation.  
We have tested the therapeutic effects of the catechin EGCg 
in RCM mice. After daily intraperitoneal administration of 50 
mg/kg body weight of EGCg over the course of 3 month, we 
observed in the echocardiography studies an improvement in 
the cardiac performance of the treated RCM cTnI193His mice as 
shown by a restored left ventricle end diastolic dimension 
(LVEDD) in M mode imaging (Figure 1). In addition, the 
hemodynamic patterns of the RCM mice were improved after 
the treatment. Pulse Wave Doppler measurement of the mitral 
valve inflow in these animals showed a less prolonged 
isovolumetric relaxation time (IVRT) compared to untreated 
RCM cTnI193His mice (Figure 2). The increased IVRT which is 
associated with impaired relaxation is the earliest manifestation 
of diastolic dysfunction in RCM animals. However, the long 
term effect of EGCg on the cardiac dysfunction and mortality 
rate still need to be studied to determine its full therapeutic 
potential for diastolic dysfunction and RCM. 
Figure 1. Decreased left ventricular end-diastolic dimension (LVEDD) 
was reversed in RCM cTnI193His mice treated with EGCg. 
 
 
Figure 2. Prolonged isovolumetric relaxation time (IVRT) was corrected in 
RCM cTnI193His mice treated with EGCg.  
IV. DISCUSSIONS 
The contractile sarcomeric proteins consist of a highly 
ordered arrangement of myosin thick filaments, actin thin 
filaments, and associated proteins, such as the troponin-
tropomyosin complex. Troponin, a contractile protein of the 
thin filament of striated muscle, consists of three subunits: 
troponin C (TnC), troponin T (TnT) and TnI. TnI is the 
inhibitory subunit which can bind to actin-tropomyosin and 
prevent muscle contraction by inhibition of actin-
tropomyosin- activated myosin (actomyosin) ATPase activity. 
It has an important function in the regulation of striated 
muscle contraction. At basal levels of calcium, TnI inhibits 
actin-myosin crossbridges. In systole, as calcium binds to the 
regulatory site of TnC, the inhibitory action of TnI is released 
thereby activating muscle contraction. Cardiac contraction-
relaxation is regulated mainly by intracellular calcium 
concentration and the proteins that are involved in the 
regulation of calcium cycling in myocardial cells, such as Ca2+ 
channel receptors, the SERCA2a calcium ATPase pump, 
phospholamban, etc. However, a body of studies has 
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demonstrated that cTnI has unique functions in the control of 
cardiac muscle contraction and relaxation. In particular, the 
key role of cTnI in myocyte relaxation indicates a direct 
contribution of the myofilaments in modulating the dynamics 
of myocardial performance. For example, PKA-mediated cTnI 
phosphorylation causes a decrease of myofibril sensitivity to 
Ca2+ or a desensitization of the contractile apparatus to 
activation by Ca2+ and an acceleration cardiac myocyte 
relaxation performance.  
Our studies have demonstrated that troponin is critical in 
the maintenance of a normal cardiac function and in the 
regulation of cardiac muscle movement. In the case of TnI 
deficiency or decrease, rest tension (Ca2+-independent force) is 
high in these myofibrils due to a tighter interaction between 
myosin and actin in the absence of TnI, which results in an 
impaired relaxation and diastolic heart failure even death. The 
fetal isoform of TnI, ssTnI, can compensate for the absence of 
cTnI by prolonging its expression time after birth. However, 
this compensation is temporary and the ssTnI gene turns off 
18 days after birth in cTnI-KO mice. It is clinically important 
to understand the TnI isoform switching and the epigenetic 
regulation of TnI gene expression since the TnI content is 
reported to be decreased in aging hearts. If we understand 
clearly the regulation of TnI gene (cTnI or ssTnI), we can 
induce the expression of the TnI gene in case the heart needs 
more TnI.  
From the studies using the transgenic RCM mice, we have 
demonstrated that hypersensitivity in RCM myocardial cells is 
a key factor that causes a delayed calcium drop-off rate from 
myofibrils and an impaired relaxation, which in turn results in 
diastolic dysfunction and heart failure. Our experimental 
therapeutic experiments have confirmed that desensitization is 
effective in correcting hypersensitivity of myofibril to Ca2+ 
and reversing the phenotype of RCM.  
Our studies indicate that to have a normal cardiac 
contraction and relaxation, calcium concentration is critical. In 
addition, myofibril sensitivity to Ca2+ is important as well. It is 
clinically important to propose this novel concept since almost 
half of the heart failure patients have diastolic dysfunction and 
no effective medication is available so far for the diastolic 
dysfunction and heart failure. Calcium desensitization may be 
useful in the treatment of diastolic dysfunction and heart 
failure.  
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